Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
Stephan von Haehling, Birgit Aßmus, Tarek Bekfani, Elke Dworatzek, Frank Edelmann, Djawid Hashemi, Kristian Hellenkamp, Tibor Kempf, Philipp Raake, Katharina Andrea Schütt, Rolf Wachter, P. Christian Schulze, Gerd Hasenfuß, Michael Böhm, Johann Bauersachs
Abstract
The aetiology of heart failure with preserved ejection fraction (HFpEF) is heterogenous and overlaps with that of several comorbidities like atrial fibrillation, diabetes mellitus, chronic kidney disease, valvular heart disease, iron deficiency, or sarcopenia. The diagnosis of HFpEF involves evaluating cardiac dysfunction through imaging techniques and assessing increased left ventricular filling pressure, which can be measured directly or estimated through various proxies including natriuretic peptides. To better narrow down the differential diagnosis of HFpEF, European and American heart failure guidelines advocate the use of different algorithms including comorbidities that require diagnosis and rigorous treatment during the evaluation process. Therapeutic recommendations differ between guidelines. Whilst sodium glucose transporter 2 inhibitors have a solid evidence base, the recommendations differ with regard to the use of inhibitors of the renin-angiotensin-aldosterone axis. Unless indicated for specific comorbidities, the use of beta-blockers should be discouraged in HFpEF. The aim of this article is to provide an overview of the current state of the art in HFpEF diagnosis, clinical evaluation, and treatment.